iBio, Inc. Appoints Chief Medical Officer, Grants 430K-Share Option

What Happened
iBio, Inc. announced on August 4, 2026 (8‑K filed) that Dr. Molly Carr, M.D. was appointed Chief Medical Officer effective July 31, 2026. The company entered into an employment agreement dated July 31, 2026, and granted Dr. Carr a 430,000-share non‑qualified stock option as an inducement award.

Key Details

• Employment start/effective date: July 31, 2026; public announcement: August 4, 2026.
• Compensation: $470,000 annual base salary and eligibility for an annual target cash bonus equal to 40% of base salary.
• Inducement Award: 430,000 stock options granted outside the 2023 Omnibus Incentive Plan; exercise price = closing price on grant date; 10‑year term. Vesting: 25% after 1 year, remaining 75% in 36 substantially equal monthly installments thereafter. Approved under Nasdaq Listing Rule 5635(c)(4).
• Severance: If terminated without Cause or resigns for Good Reason, Dr. Carr is eligible (upon release) for nine months of base‑salary continuation, prorated bonus, and nine months of COBRA; enhanced package (12 months base pay, target bonus cash payment, full vesting acceleration of time‑based equity, and 12 months COBRA) applies if termination occurs around a Sale Event.
• Background: Dr. Carr is an experienced physician executive with prior roles at Eli Lilly, GlaxoSmithKline, CSL Behring and Wyeth, and academic appointments; board‑certified in Endocrinology, Diabetes & Metabolism and Internal Medicine. The company noted no family relationships or related‑party transactions requiring disclosure.

Why It Matters
This 8‑K reports a senior executive hire in a clinical leadership role and a sizable equity inducement designed to align Dr. Carr’s incentives with company performance and retention. Investors should note the potential dilution from the 430,000‑share option and the compensation and severance commitments that could affect cash flow or equity on certain termination or change‑of‑control scenarios. The filing also reflects compliance with Nasdaq rules for inducement grants.